WO2008074080A1 - Composition and method for treatment of ibs - Google Patents

Composition and method for treatment of ibs Download PDF

Info

Publication number
WO2008074080A1
WO2008074080A1 PCT/AU2007/001968 AU2007001968W WO2008074080A1 WO 2008074080 A1 WO2008074080 A1 WO 2008074080A1 AU 2007001968 W AU2007001968 W AU 2007001968W WO 2008074080 A1 WO2008074080 A1 WO 2008074080A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginger
fennel
peppermint
composition according
oil
Prior art date
Application number
PCT/AU2007/001968
Other languages
French (fr)
Inventor
David Lubowski
Original Assignee
David Lubowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006907115A external-priority patent/AU2006907115A0/en
Application filed by David Lubowski filed Critical David Lubowski
Priority to AU2007335255A priority Critical patent/AU2007335255A1/en
Publication of WO2008074080A1 publication Critical patent/WO2008074080A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235Foeniculum (fennel)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals

Definitions

  • the invention relates to compositions and methods for the treatment of irritable bowel syndrome (IBS) or the amelioration of symptoms thereof.
  • IBS irritable bowel syndrome
  • IBS irritable bowel syndrome
  • the condition causes a number of symptoms which occur alone or in various combinations. Abdominal bloating, pain, flatulence (wind), diarrhea, or constipation (or intermittent bouts of both) may all occur. In some cases pain is intermittently very severe and can lead to time off work.
  • IBS is more common in women than men.
  • Constipation may be mild or severe. Using colon transit studies, transit time through the colon is found to be normal in IBS, which distinguishes the condition from other forms of constipation. Diarrhoea may also vary in severity, and varies from day to day. The cause and pathophysiology of IBS remains unclear. The bowel has been shown to be particularly sensitive to distension and this may be one of the mechanisms causing pain. The presence of contrary symptoms, such as constipation and diarrhea occurring in the same condition, or even intermittently in the same patient, underscores the lack of understanding of the condition.
  • IBS intracranial pressure
  • Conventional medications for treatment of constipation ie laxatives
  • diarrhoea anti-diarrhoeal medications
  • Anti-spasmodic drugs such as Buscopan and Colofac are commonly used.
  • Peppermint has also been shown to be effective for IBS in a number of studies. There are a number of proprietary formulations of peppermint oil capsules on the market. These capsules typically contain 0.2 ml of peppermint in an enteric coated capsule for release of the peppermint in the intestine (rather than in the stomach). This represents a standardised dose that can be readily taken at any time. Compliance with treatment with peppermint capsules is usually very good.
  • Fennel and ginger are also known to relieve symptoms such as bloating, flatulence and pain.
  • Fennel is most readily available as a fresh herb. Ginger is available in many forms, either natural or sweetened. Fresh fennel is taken most conveniently with a meal at home, however, this is difficult to achieve for patients who work or who are away from home. Even while at home it may not be convenient to take fennel or ginger other than when the patient remembers to do so, or is sitting down to a formal meal. Also, under those circumstances, it can be difficult to achieve a standardised dosage of ginger or fennel.
  • the invention provides a composition for the treatment of irritable bowel syndrome (IBS) including a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
  • IBS irritable bowel syndrome
  • the invention provides a composition for the amelioration of one or more symptoms of irritable bowel syndrome (IBS) including a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
  • IBS irritable bowel syndrome
  • the symptoms of IBS include, but are not limited to, one or more of bloating, flatulence or pain.
  • the symptoms may be a combination of bloating and flatulence, a combination of bloating and pain or a combination of flatulence and pain.
  • the symptoms may also be a combination of bloating, flatulence and pain.
  • the peppermint is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of peppermint oil. More preferably, the peppermint is administered in a dose equivalent to 200-250 mg of peppermint oil. Most preferably, the peppermint is administered as 200-250 mg of peppermint oil
  • the ginger is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of ginger oil. More preferably, the ginger is administered in a dose equivalent to 100-150 mg of ginger oil. Most preferably, the ginger is administered as 100-150 mg of ginger oil.
  • the fennel is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of fennel oil. More preferably the fennel is administered in a dose equivalent to 100-150 mg of fennel oil. Most preferably the fennel is administered as 100-150 mg of fennel oil.
  • the dosage includes, in independently variable amounts, peppermint in an amount equivalent to 200-250 mg of peppermint oil, ginger in an amount equivalent to 100-150 mg of ginger oil and fennel oil in an amount equivalent to 100-150 mg of fennel oil. More preferably the dosage includes, in independently variable amounts, 200-250 mg of peppermint oil, 100-150 mg of ginger oil and 100-150 mg of fennel oil.
  • One highly preferred embodiment is in the form of a 500 mg dosage form including 200 mg peppermint oil, 150 mg ginger oil and 150 mg fennel oil.
  • compositions of the present invention are provided in the form of a capsule, which may be an enteric capsule or a capsule suitable for release in the stomach. More preferably, the compositions are provided in the form of an enteric coated capsule.
  • compositions of the present invention are provided in the form of a syrup.
  • compositions of the present invention that the weight ratio of peppermint oil:ginger oil: fennel oil is from around 1.33:1:1 to around 2.5:1 :1, although any ratio which meets the criteria set forth previously for therapeutic efficacy of each component is acceptable.
  • the peppermint, ginger and fennel may be present as dry ingredients.
  • the dry ingredients are each present in a therapeutically effective amount, up to an amount equivalent to 50 ml of peppermint oil, ginger oil or fennel oil.
  • the dry peppermint is administered in a dose equivalent to 200-250 mg of peppermint oil.
  • the dry ginger is administered in a dose equivalent to 100-150 mg of ginger oil.
  • the dry fennel is administered in a dose equivalent to 100-150 mg of fennel oil.
  • the dry ingredients are blended in the form of a desiccated powder.
  • the dry ingredients may be compressed into a tablet.
  • the formulations of the present invention may also include one or more additional substances efficacious in treating IBS, or one or more additional substances efficacious in treating one or more symptoms of IBS.
  • these substances may be selected from: Yarrow (achillea millefolium), Witch Hazel (hamamelis virginiana), Horsetail (equiseti herba), and Aloe vera species.
  • the invention provides a method of treating IBS including the step of administering to a subject in need thereof a composition according to the present invention.
  • the invention provides a method of treating one or more symptoms of IBS including the step of administering to a subject in need thereof a composition according to the present invention.
  • the invention provides a method of treating either alone or in combination, any of bloating flatulence or abdominal pain including the step of administering to a subject in need thereof a composition according to the present invention.
  • the peppermint, ginger and fennel are all present in a therapeutically effective amount.
  • the invention provides the use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of IBS.
  • the invention provides the use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of one or more symptoms of IBS.
  • the invention provides the use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of, either alone or in combination, any of bloating, flatulence or abdominal pain.
  • the peppermint, ginger and fennel are all present in a therapeutically effective amount.
  • the invention provides a method of increasing patient compliance with a course of ginger and fennel including the step of formulating ginger and fennel with peppermint prior to administering the combination of peppermint, ginger and fennel to the patient.
  • the invention provides a method of increasing patient compliance and increasing efficacy against IBS or symptoms thereof of a course of ginger and fennel including the step of formulating ginger and fennel with peppermint prior to administering the combination of peppermint, ginger and fennel to the patient.
  • the invention provides a method for the treatment of IBS or the amelioration of the symptoms thereof comprising administering to a subject in need thereof a combination of a therapeutically effective amount of peppermint, a therapeutically effective amount of fennel and a therapeutically effective amount of ginger.
  • the peppermint, fennel and ginger are administered simultaneously, either in a single dose.
  • they may be administered in the form of individual dosage forms of each substance taken together at the same or substantially the same time.
  • the invention also encompasses the administration of the three substances at staggered intervals, with a view to achieving the synergistic benefits of the interaction of the three compounds.
  • the invention also provides a method of treating IBS including the step of administering to a subject in need thereof a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
  • a clinician would, if necessary, readily be able to adjust the dosages and ratios as provided above, to compensate for non-simultaneous ingestion of one or more of the peppermint, fennel or ginger.
  • Non simultaneous ingestion may be required if one or more of the substances is not well tolerated.
  • the invention relates to the administration of compositions including therapeutically effective amounts of peppermint, ginger and fennel to IBS sufferers for the treatment of IBS or the amelioration of the symptoms of IBS.
  • compositions Whilst each of these compositions has been used individually in IBS treatments, it has not been known before to simultaneously administer therapeutically effective amounts of all three.
  • a therapeutic amount of peppermint, fennel or ginger would be regarded as 50 mg (or 0.05 ml of peppermint, ginger or fennel oil).
  • a therapeutic amount of peppermint is more preferably in the region of 200-250 mg of peppermint oil, or an equivalent amount of active ingredients obtained from, for example, fresh or dried peppermint.
  • Therapeutic amounts of ginger and fennel have been found to be more preferably in the region of 100-150 mg of ginger or fennel oil respectively, or an equivalent amount of actives obtained from fresh or dried product.
  • the compounds need to be administered not only in therapeutic amounts, but also substantially together. Ideally, this is in the form of a single dose which has all three, but it could be that therapeutic amounts of each are taken individually at the same time, or multiple smaller doses are taken at the same time. A person of ordinary skill in the art would easily be able to determine any combination of dosages and amounts which ensure that the desired simultaneous loading of all three components was achieved.
  • One particularly preferred dosage form is a capsule that provides 200 mg peppermint oil, 150 mg ginger oil and 150 mg fennel oil.
  • Another highly preferred dosage form is a capsule that provides about 250mg peppermint, about 150 mg of ginger and about 100 mg of fennel.
  • the weight of the actives is about 500mg in total.
  • the dosage form may also contain other excipients, such as stabilizers and the like in amounts as dictated by the formulation. Typically, these would amount to less than 0.05 ml.
  • compositions of the present invention can be administered once, twice or three times a day at an appropriate spacing, or as otherwise directed by the physician.
  • the dosages need to be formulated bearing in mind that the critical therapeutically effective loading of each dosage needs to be applied at each administration.
  • a course of tablets where peppermint, ginger and fennel were administered in spaced apart doses where for example 200 mg peppermint, 100 mg fennel and 100 mg ginger were administered in total over three equally spaced apart doses would not be expected to provide the benefits of the present invention, since at no time was any effective therapeutic loading achieved.
  • the physician may also choose to increase the dosage of any or all of the components, typically in the range 0.5 to 50 ml oil or an equivalent of fresh or dried material.
  • the dosage form most preferred is a capsule containing a mixture of all three components, as outlined above. Any suitable conventional capsule forms may be used. Enteric capsules are preferred.
  • compositions may be in the form of syrup, that is a liquid, which has been flavoured in such a way as to allow the combination to be administered by mouth.
  • syrup would contain dosages of the active agents equivalent in dosage to the amounts described above.
  • the dosage form may be in powdered form in a container or sealed package, where each component is a desiccated powder.
  • the amount of each component is standardised, and is equivalent in dosage to the amounts described above.
  • the dry components may also be compressed into a tablet.
  • Oil components may be mixed with a dry inert matrix agent for compression into a tablet.
  • the components may also be presented to the patient in the form of a food, for example, a cookie or food bar or a drink, shake or similar.
  • the formulations may also be expressed in terms of the ratio of components.
  • Preferred ratios ofpeppermint:ginger:fennel are: 2:1 :1, 2:1 : 1.5, 2:1.5:1.5, 2: 1.5:1, 2.5: 1 :1, 2.5:1 :1.5, 2.5: 1.5:1.5, 2.5:1.5:1. It needs to be borne in mind that in addition to these ratios, a therapeutically effective amount of each component needs to be added.
  • the present invention may also include other substances which may be efficacious in treating IBS including Yarrow (achillea millefolium), Witch Hazel (hamamelis virginiana), Horsetail (equiseti herba), and Aloe vera species.
  • the present applicant has observed that a combination of fennel, ginger and peppermint, taken at the same time, provides an effective treatment for bloating, flatulence and pain in some patients.
  • IBS irritable bowel syndrome
  • the high levels of patient compliance and high efficacy of the composition of the present invention means that the combination of therapeutically effective amounts of fennel, ginger and peppermint has been found to be unusually effective in the treatment of IBS and the symptoms thereof.

Abstract

The invention relates to compositions and methods for the treatment or amelioration of one or more symptoms of irritable bowel syndrome, such as bloating, flatulence or pain. The compositions include a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger, and may be in the form of a capsule for example. Additional substances may be included in the compositions and methods, such as Yarrow (achillea millefolium), Witch Hazel (hamamelis virginiana), Horsetail (equiseti herba), and Aloe vera species. In the methods of the present invention, the peppermint, ginger and fennel may be administered together or separately, at the same time or at staggered times.

Description

TITLE: COMPOSITION AND METHOD FOR TREATMENT OF IBS
TECHNICAL FIELD
The invention relates to compositions and methods for the treatment of irritable bowel syndrome (IBS) or the amelioration of symptoms thereof.
BACKGROUND
The precise prevalence of irritable bowel syndrome (IBS) is unknown, but it is undoubtedly a very common condition and a common reason for visits to the general practitioner as well as specialist gastroenterologist and surgeon.
The condition causes a number of symptoms which occur alone or in various combinations. Abdominal bloating, pain, flatulence (wind), diarrhea, or constipation (or intermittent bouts of both) may all occur. In some cases pain is intermittently very severe and can lead to time off work.
It may begin at a young age, not uncommonly in the late teens, but may also occur later in life. In some cases it mysteriously burns out and symptoms resolve, but in other cases it may persist for many years or may even be a life-long condition. IBS is more common in women than men.
The extent of bloating may vary during the day, and it not uncommon for young female patients to complain that by the end of the day they appear as though they are pregnant. Some patients need to loosen or re-tighten their clothing during the day as swelling changes.
Constipation may be mild or severe. Using colon transit studies, transit time through the colon is found to be normal in IBS, which distinguishes the condition from other forms of constipation. Diarrhoea may also vary in severity, and varies from day to day. The cause and pathophysiology of IBS remains unclear. The bowel has been shown to be particularly sensitive to distension and this may be one of the mechanisms causing pain. The presence of contrary symptoms, such as constipation and diarrhea occurring in the same condition, or even intermittently in the same patient, underscores the lack of understanding of the condition.
Many forms of treatment have been tried for IBS. Conventional medications for treatment of constipation (ie laxatives) or diarrhoea (anti-diarrhoeal medications) are used to treat these facets of the condition. However, other manifestations such as pain, flatulence and bloating are particularly difficult to treat. Anti-spasmodic drugs such as Buscopan and Colofac are commonly used.
Peppermint has also been shown to be effective for IBS in a number of studies. There are a number of proprietary formulations of peppermint oil capsules on the market. These capsules typically contain 0.2 ml of peppermint in an enteric coated capsule for release of the peppermint in the intestine (rather than in the stomach). This represents a standardised dose that can be readily taken at any time. Compliance with treatment with peppermint capsules is usually very good.
Fennel and ginger are also known to relieve symptoms such as bloating, flatulence and pain. Fennel is most readily available as a fresh herb. Ginger is available in many forms, either natural or sweetened. Fresh fennel is taken most conveniently with a meal at home, however, this is difficult to achieve for patients who work or who are away from home. Even while at home it may not be convenient to take fennel or ginger other than when the patient remembers to do so, or is sitting down to a formal meal. Also, under those circumstances, it can be difficult to achieve a standardised dosage of ginger or fennel.
There remains the need for further treatment of IBS and/or symptoms thereof.
Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field. SUMMARY OF THE INVENTION
According to a first aspect, the invention provides a composition for the treatment of irritable bowel syndrome (IBS) including a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
In another aspect, the invention provides a composition for the amelioration of one or more symptoms of irritable bowel syndrome (IBS) including a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
Preferably the symptoms of IBS include, but are not limited to, one or more of bloating, flatulence or pain. The symptoms may be a combination of bloating and flatulence, a combination of bloating and pain or a combination of flatulence and pain. The symptoms may also be a combination of bloating, flatulence and pain.
Preferably, the peppermint is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of peppermint oil. More preferably, the peppermint is administered in a dose equivalent to 200-250 mg of peppermint oil. Most preferably, the peppermint is administered as 200-250 mg of peppermint oil
Preferably, the ginger is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of ginger oil. More preferably, the ginger is administered in a dose equivalent to 100-150 mg of ginger oil. Most preferably, the ginger is administered as 100-150 mg of ginger oil.
Preferably the fennel is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of fennel oil. More preferably the fennel is administered in a dose equivalent to 100-150 mg of fennel oil. Most preferably the fennel is administered as 100-150 mg of fennel oil.
In the present invention. It is preferable that the dosage includes, in independently variable amounts, peppermint in an amount equivalent to 200-250 mg of peppermint oil, ginger in an amount equivalent to 100-150 mg of ginger oil and fennel oil in an amount equivalent to 100-150 mg of fennel oil. More preferably the dosage includes, in independently variable amounts, 200-250 mg of peppermint oil, 100-150 mg of ginger oil and 100-150 mg of fennel oil. One highly preferred embodiment is in the form of a 500 mg dosage form including 200 mg peppermint oil, 150 mg ginger oil and 150 mg fennel oil.
In one preferred embodiment, the compositions of the present invention are provided in the form of a capsule, which may be an enteric capsule or a capsule suitable for release in the stomach. More preferably, the compositions are provided in the form of an enteric coated capsule.
In an alternative preferred embodiment, the compositions of the present invention are provided in the form of a syrup.
It is preferred in the compositions of the present invention that the weight ratio of peppermint oil:ginger oil: fennel oil is from around 1.33:1:1 to around 2.5:1 :1, although any ratio which meets the criteria set forth previously for therapeutic efficacy of each component is acceptable.
In an alternative embodiment, the peppermint, ginger and fennel may be present as dry ingredients. In that case, it is preferred that the dry ingredients are each present in a therapeutically effective amount, up to an amount equivalent to 50 ml of peppermint oil, ginger oil or fennel oil.
Preferably the dry peppermint is administered in a dose equivalent to 200-250 mg of peppermint oil. Preferably the dry ginger is administered in a dose equivalent to 100-150 mg of ginger oil. Preferably the dry fennel is administered in a dose equivalent to 100-150 mg of fennel oil.
In one dry dosage form, the dry ingredients are blended in the form of a desiccated powder. Alternatively, the dry ingredients may be compressed into a tablet. The formulations of the present invention may also include one or more additional substances efficacious in treating IBS, or one or more additional substances efficacious in treating one or more symptoms of IBS. For preference, these substances may be selected from: Yarrow (achillea millefolium), Witch Hazel (hamamelis virginiana), Horsetail (equiseti herba), and Aloe vera species.
In another broad aspect, the invention provides a method of treating IBS including the step of administering to a subject in need thereof a composition according to the present invention.
In another aspect, the invention provides a method of treating one or more symptoms of IBS including the step of administering to a subject in need thereof a composition according to the present invention. In one particular aspect, the invention provides a method of treating either alone or in combination, any of bloating flatulence or abdominal pain including the step of administering to a subject in need thereof a composition according to the present invention. The peppermint, ginger and fennel are all present in a therapeutically effective amount.
In another aspect, the invention provides the use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of IBS.
In another aspect, the invention provides the use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of one or more symptoms of IBS. In one particular aspect, the invention provides the use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of, either alone or in combination, any of bloating, flatulence or abdominal pain. The peppermint, ginger and fennel are all present in a therapeutically effective amount.
In yet another aspect, the invention provides a method of increasing patient compliance with a course of ginger and fennel including the step of formulating ginger and fennel with peppermint prior to administering the combination of peppermint, ginger and fennel to the patient. In yet another aspect, the invention provides a method of increasing patient compliance and increasing efficacy against IBS or symptoms thereof of a course of ginger and fennel including the step of formulating ginger and fennel with peppermint prior to administering the combination of peppermint, ginger and fennel to the patient.
In yet another aspect, the invention provides a method for the treatment of IBS or the amelioration of the symptoms thereof comprising administering to a subject in need thereof a combination of a therapeutically effective amount of peppermint, a therapeutically effective amount of fennel and a therapeutically effective amount of ginger. Ideally, the peppermint, fennel and ginger are administered simultaneously, either in a single dose. However, equally effectively, they may be administered in the form of individual dosage forms of each substance taken together at the same or substantially the same time.
Also, whilst the invention is described with reference to simultaneous or substantially simultaneous administration, the invention also encompasses the administration of the three substances at staggered intervals, with a view to achieving the synergistic benefits of the interaction of the three compounds.
Accordingly, the invention also provides a method of treating IBS including the step of administering to a subject in need thereof a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
A clinician would, if necessary, readily be able to adjust the dosages and ratios as provided above, to compensate for non-simultaneous ingestion of one or more of the peppermint, fennel or ginger. Non simultaneous ingestion may be required if one or more of the substances is not well tolerated. DESCRIPTION
The invention relates to the administration of compositions including therapeutically effective amounts of peppermint, ginger and fennel to IBS sufferers for the treatment of IBS or the amelioration of the symptoms of IBS.
Whilst each of these compositions has been used individually in IBS treatments, it has not been known before to simultaneously administer therapeutically effective amounts of all three. Generally, a therapeutic amount of peppermint, fennel or ginger would be regarded as 50 mg (or 0.05 ml of peppermint, ginger or fennel oil). A therapeutic amount of peppermint is more preferably in the region of 200-250 mg of peppermint oil, or an equivalent amount of active ingredients obtained from, for example, fresh or dried peppermint. Therapeutic amounts of ginger and fennel have been found to be more preferably in the region of 100-150 mg of ginger or fennel oil respectively, or an equivalent amount of actives obtained from fresh or dried product.
A number of formulations of peppermint are available which contain additional agents, but these additional agents are often present in sub therapeutic amounts, or in non-standardised doses. Herbal remedies for example usually contain numerous active agents or potentially active agents, however, the dosages are non standard and often in sub therapeutic quantities.
The compounds need to be administered not only in therapeutic amounts, but also substantially together. Ideally, this is in the form of a single dose which has all three, but it could be that therapeutic amounts of each are taken individually at the same time, or multiple smaller doses are taken at the same time. A person of ordinary skill in the art would easily be able to determine any combination of dosages and amounts which ensure that the desired simultaneous loading of all three components was achieved.
One particularly preferred dosage form is a capsule that provides 200 mg peppermint oil, 150 mg ginger oil and 150 mg fennel oil. Another highly preferred dosage form is a capsule that provides about 250mg peppermint, about 150 mg of ginger and about 100 mg of fennel. The weight of the actives is about 500mg in total. The dosage form may also contain other excipients, such as stabilizers and the like in amounts as dictated by the formulation. Typically, these would amount to less than 0.05 ml.
Multiple tablets or capsules of smaller amounts could be used, eg two tablets having 100 mg peppermint, 75 mg ginger and 75 mg fennel, however these suffer from the drawback that if a single tablet is taken, which is possible for patients looking to extend their supply of medication, the dosage loadings will be sub-therapeutic.
The compositions of the present invention can be administered once, twice or three times a day at an appropriate spacing, or as otherwise directed by the physician. The dosages need to be formulated bearing in mind that the critical therapeutically effective loading of each dosage needs to be applied at each administration. A course of tablets where peppermint, ginger and fennel were administered in spaced apart doses where for example 200 mg peppermint, 100 mg fennel and 100 mg ginger were administered in total over three equally spaced apart doses would not be expected to provide the benefits of the present invention, since at no time was any effective therapeutic loading achieved.
The physician may also choose to increase the dosage of any or all of the components, typically in the range 0.5 to 50 ml oil or an equivalent of fresh or dried material.
However, at each administration, it is important to get the appropriate therapeutically effective loading of all three components.
The dosage form most preferred is a capsule containing a mixture of all three components, as outlined above. Any suitable conventional capsule forms may be used. Enteric capsules are preferred.
However, delivery methods other than a capsule may also be used. The composition may be in the form of syrup, that is a liquid, which has been flavoured in such a way as to allow the combination to be administered by mouth. Again, the syrup would contain dosages of the active agents equivalent in dosage to the amounts described above.
Alternatively, the dosage form may be in powdered form in a container or sealed package, where each component is a desiccated powder. The amount of each component is standardised, and is equivalent in dosage to the amounts described above.
Alternatively, the dry components may also be compressed into a tablet. Oil components may be mixed with a dry inert matrix agent for compression into a tablet.
Although less preferred, the components may also be presented to the patient in the form of a food, for example, a cookie or food bar or a drink, shake or similar.
The formulations may also be expressed in terms of the ratio of components.
Preferred ratios ofpeppermint:ginger:fennel are: 2:1 :1, 2:1 : 1.5, 2:1.5:1.5, 2: 1.5:1, 2.5: 1 :1, 2.5:1 :1.5, 2.5: 1.5:1.5, 2.5:1.5:1. It needs to be borne in mind that in addition to these ratios, a therapeutically effective amount of each component needs to be added.
In addition to peppermint, ginger and fennel, the present invention may also include other substances which may be efficacious in treating IBS including Yarrow (achillea millefolium), Witch Hazel (hamamelis virginiana), Horsetail (equiseti herba), and Aloe vera species.
The present applicant has observed that a combination of fennel, ginger and peppermint, taken at the same time, provides an effective treatment for bloating, flatulence and pain in some patients.
The combination of fennel, ginger and peppermint is more effective than peppermint alone, and is more effective than ginger and fennel alone. It has also been observed that compliance with formulations containing peppermint is generally very good, much better than compliance with ginger and fennel, which, in whatever form, is generally quite poor.
In the present case, the combination of peppermint with ginger and fennel generally results in high levels of compliance.
CLINICAL STUDIES
26 Patients with symptoms of irritable bowel syndrome (IBS) were treated with a combination of peppermint, ginger, and fennel in accordance with the present invention.
Patients had various symptoms including abdominal pain, bloating, distension, and flatulence ("wind").
Patients were asked to use 0.2ml peppermint capsules, one square piece of ginger, and an equivalent amount of fennel. The dosages of ginger and fennel administered were not quantified in more detail, but should generally ensure that therapeutic amounts of each substance were consumed.
24 Patients from the group could be contacted and were followed up at a suitable time either at their visit or by telephone. The patients were asked about improvements or changes in pain, bloating, wind, and abdominal distension. Diarrhoea was not assessed since this symptom, although not infrequent in patients with IBS5 is affected by multiple other factors including other medications.
17 (71%) Patients had partial or significant improvement in symptoms. 12 Patients had improvement in pain, 3 patients had improvement in bloating and wind, and 2 had improvement in pain and bloating. Seven (29%) were not improved, with symptoms continuing as before. No patient had worsening of symptoms during the follow-up period. More than two thirds of patients reported an improvement in symptoms with combinations of peppermint, ginger and fennel. As there is currently no approved treatment which reliably improves symptoms of IBS, achieving improvements in 71% of patients is considered a very good outcome.
Compliance with treatment was not quantified in the follow-up audit, so it is unknown whether patients reliably took all three substances. However, it seems that compliance with the use of peppermint and ginger is more reliable than the use of fennel as a result of the more ready availability.
Some patients did not tolerate raw ginger, which is generally less palatable than sugar-coated ginger. Patients were encouraged to take sugar-coated ginger if desired.
The high levels of patient compliance and high efficacy of the composition of the present invention means that the combination of therapeutically effective amounts of fennel, ginger and peppermint has been found to be unusually effective in the treatment of IBS and the symptoms thereof.

Claims

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-
1. A composition for the treatment of irritable bowel syndrome IBS including a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
2. A composition for the amelioration of one or more symptoms of irritable bowel syndrome IBS including a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
3. A composition according to claim 2 wherein the one or more symptoms is one or more of bloating, flatulence or pain.
4. A composition according to claim 3 wherein the one or more symptoms are a combination of bloating and flatulence, a combination of bloating and pain or a combination of flatulence and pain.
5. A composition according to claim 1 wherein the one or more symptoms of are a combination of bloating, flatulence and pain.
6. A composition according to any one of the preceding claims wherein the peppermint is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of peppermint oil.
7. A composition according to claim 6 wherein the peppermint is administered in a dose equivalent to 200-250 mg of peppermint oil
8. A composition according to claim 7 including 200-250 mg of peppermint oil
9. A composition according to any one of the preceding claims wherein the ginger is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of ginger oil.
10. A composition according to claim 9 wherein the ginger is administered in a dose equivalent to 100-150 mg of ginger oil
11. A composition according to claim 10 including 100-150 mg of ginger oil.
12. A composition according to any one of the preceding claims wherein the fennel is administered in a therapeutically effective amount up to an amount equivalent to 50 ml of fennel oil.
13. A composition according to any one of the preceding claims wherein the fennel is administered in a dose equivalent to 100-150 mg of fennel oil.
14. A composition according to claim 10 including 100-150 mg of fennel oil.
15. A composition according to any one of the preceding claims wherein the dosage includes in independently variable amounts peppermint in an amount equivalent to 200- 250 mg of peppermint oil, ginger in an amount equivalent to 100-150 mg of ginger oil and fennel oil in an amount equivalent to 100-150 mg of fennel oil.
16. A composition according to claim 15 wherein the dosage includes in independently variable amounts 200-250 mg of peppermint oil, 100-150 mg of ginger oil and 100-150 mg of fennel oil.
17. A composition according to claim 16 in the form of a 500 mg dosage form including 200 mg peppermint oil, 150 mg ginger oil and 150 mg fennel oil.
18. A composition according to any one of the preceding claims in the form of a capsule.
19. A composition according to claim 18 in the form of an enteric coated capsule.
20. A composition according to any one of claimsl-17 in the form of a syrup.
21. A composition according to any one of the preceding claims wherein the weight ratio of peppermint oihginger oil: fennel oil is 1.33:1:1.
22. A composition according to claim 21 wherein the weight ratio of peppermint oil:ginger oil: fennel oil is 2.5:1:1
23. A composition according to any one of claims 1 to 5 wherein the peppermint, ginger and fennel are present as dry ingredients.
24. A composition according to claim 23 wherein the dry ingredients are each present in a therapeutically effective amount, up to an amount equivalent to 50 of peppermint oil, ginger oil or fennel oil.
25. A composition according to claim 24 wherein the dry peppermint is administered in a dose equivalent to 200-250 mg of peppermint oil
26. A composition according to any one of claims 24-25 wherein the dry ginger is administered in a dose equivalent to 100-150 mg of ginger oil
27. A composition according to any one of claims 24-26 wherein the dry fennel is administered in a dose equivalent to 100-150 mg of fennel oil
28. A composition according to any one of claims 23-27 wherein the dry ingredients are blended in the form of a desiccated powder
29. A composition according to any one of claims 23-28 wherein the dry ingredients are compressed into a tablet.
30. A composition according to any one of the preceding claims including one or more additional substances efficacious in treating IBS.
31. A composition according to any one of the preceding claims including one or more additional substances efficacious in treating one or more symptoms of IBS.
32. A composition according to claim 30 or 31 wherein the additional substances are selected from: Yarrow (achillea millefolium), Witch Hazel (hamamelis virginiana), Horsetail (equiseti herba), and Aloe vera species.
33. A method of treating IBS including the step of administering to a subject in need thereof a combination of a therapeutic dose of peppermint, a therapeutic dose of fennel and a therapeutic dose of ginger.
34. A method of treating IBS including the step of administering to a subject in need thereof a composition according to any one of claims 1 to 32.
35. A method of treating one or more symptoms of IBS including the step of administering to a subject in need thereof a composition according to any one of claims 1 to 32.
36. A method of treating bloating including the step of administering to a subject in need thereof a composition according to any one of claims 1 to 32.
37. A method of treating flatulence including the step of administering to a subject in need thereof a composition according to any one of claims 1 to 32.
39. A method of treating abdominal pain including the step of administering to a subject in need thereof a composition according to any one of claims 1 to 32.
40. The use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of IBS.
41. The use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of one or more symptoms of IBS.
42. The use of a combination of peppermint, ginger and fennel for the manufacture of a medicament for the treatment of bloating.
43. The use of a combination of peppermint ginger and fennel for the manufacture of a medicament for the treatment of flatulence.
44. The use of a combination of peppermint ginger and fennel for the manufacture of a medicament for the treatment of abdominal pain.
45. The use according to any one of claims 40 to 44 wherein the peppermint, ginger and femiel are all present in a therapeutically effective amount.
46. A method of increasing patient compliance with a course of ginger and fennel including the step of formulating ginger and fennel with peppermint
47. A method of increasing patient compliance and increasing efficacy of a course of ginger and fennel including the step of formulating ginger and fennel with peppermint.
48. A capsule including about 250 mg peppermint oil, about 150 mg ginger oil and about 100 mg fennel oil.
49. A capsule according to claim 46 including one or more excipients such as stabilizers and the like.
PCT/AU2007/001968 2006-12-20 2007-12-19 Composition and method for treatment of ibs WO2008074080A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007335255A AU2007335255A1 (en) 2006-12-20 2007-12-19 Composition and method for treatment of IBS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006907115 2006-12-20
AU2006907115A AU2006907115A0 (en) 2006-12-20 Composition and method for treatment of IBS

Publications (1)

Publication Number Publication Date
WO2008074080A1 true WO2008074080A1 (en) 2008-06-26

Family

ID=39535888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2007/001968 WO2008074080A1 (en) 2006-12-20 2007-12-19 Composition and method for treatment of ibs

Country Status (2)

Country Link
AU (1) AU2007335255A1 (en)
WO (1) WO2008074080A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083968A1 (en) * 2009-01-20 2010-07-29 Indena S.P.A. Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
ITMI20091358A1 (en) * 2009-07-29 2011-01-30 Indena Spa COMPOSITIONS BASED ON LIPOPHILUS EXTRACT OF ZINGIBER OFFICINAL AND CYNARA SCOLYMUS EXTRACT FOR THE PREVENTION AND TREATMENT OF EXOPHAGEAL REFLOW AND IRRITABLE COLON SYNDROME
WO2012130351A1 (en) * 2011-03-25 2012-10-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition for use for digestive problems
WO2016041826A1 (en) * 2014-09-16 2016-03-24 Alfa Wassermann Spa Therapeutic and nutritional compositions for functional gastrointestinal disorders.
IT201700082310A1 (en) * 2017-07-20 2017-10-20 Gianfranco Caramelli "Treatment of complex gastrointestinal symptoms associated with IBS (Irritable bowel syndrome) with microencapsulated Peppermint essential oil associated with natural principles"

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613362B2 (en) * 2002-01-08 2003-09-02 Renew Life Formulas, Inc. Herbal formulation which acts as an intestinal bowel soother
US20060115468A1 (en) * 2004-11-26 2006-06-01 Kara Morrison Dietary supplement for treating and preventing gastrointestinal disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613362B2 (en) * 2002-01-08 2003-09-02 Renew Life Formulas, Inc. Herbal formulation which acts as an intestinal bowel soother
US20060115468A1 (en) * 2004-11-26 2006-06-01 Kara Morrison Dietary supplement for treating and preventing gastrointestinal disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HERLFORIBS.COM: "Heather's Tummy Tamers Data Sheet", HEATHER & CO., PEPPERMINT CAPSULES, 29 October 2006 (2006-10-29), Retrieved from the Internet <URL:http://www.web.archive.org/web/20061029154643> *
NUTRASANUS: "Peppermint Gels. Data sheet", 11 July 2006 (2006-07-11), Retrieved from the Internet <URL:http://www.web.archive.org/web/20060711175859> *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101762388B1 (en) 2009-01-20 2017-07-28 인데나 에스.피.에이 Compositions comprising a lipophilic extract of Zingiber officinale and an extract of Cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
JP2012515716A (en) * 2009-01-20 2012-07-12 インデナ エッセ ピ ア Composition comprising ginger lipophilic extract and artichoke extract useful for prevention and treatment of esophageal reflux and irritable bowel syndrome
RU2521250C2 (en) * 2009-01-20 2014-06-27 Индена С.П.А. Compositions containing lipophilic extract of zingiber officinale and extract of cynara scolymus used for preventing and treating gastroesophageal reflux and inflammatory bowel syndrome
AU2010206327B2 (en) * 2009-01-20 2015-06-04 Indena S.P.A. Compositions comprising a lipophilic extract of Zingiber officinale and an extract of Cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
WO2010083968A1 (en) * 2009-01-20 2010-07-29 Indena S.P.A. Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
US10220065B2 (en) 2009-01-20 2019-03-05 Indena S.P.A. Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
ITMI20091358A1 (en) * 2009-07-29 2011-01-30 Indena Spa COMPOSITIONS BASED ON LIPOPHILUS EXTRACT OF ZINGIBER OFFICINAL AND CYNARA SCOLYMUS EXTRACT FOR THE PREVENTION AND TREATMENT OF EXOPHAGEAL REFLOW AND IRRITABLE COLON SYNDROME
WO2012130351A1 (en) * 2011-03-25 2012-10-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition for use for digestive problems
WO2016041826A1 (en) * 2014-09-16 2016-03-24 Alfa Wassermann Spa Therapeutic and nutritional compositions for functional gastrointestinal disorders.
CN106793822A (en) * 2014-09-16 2017-05-31 意大利阿尔法韦士曼制药公司 For the composition for the treatment of and the nutrition of functional gastrointestina disorder
US10258657B2 (en) 2014-09-16 2019-04-16 Alfasigma S.P.A. Therapeutic and nutritional compositions for functional gastrointestinal disorders
EA033297B1 (en) * 2014-09-16 2019-09-30 Альфасигма С.П.А. Therapeutic and nutritional compositions for functional gastrointestinal disorders
IT201700082310A1 (en) * 2017-07-20 2017-10-20 Gianfranco Caramelli "Treatment of complex gastrointestinal symptoms associated with IBS (Irritable bowel syndrome) with microencapsulated Peppermint essential oil associated with natural principles"

Also Published As

Publication number Publication date
AU2007335255A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
EP1663257B1 (en) Use of laxatives for treating irritable bowel syndrome
EP0123469B1 (en) Use of fluoxetine for the manufacture of an anti-anxiety agent
EP2070545A1 (en) Oral compositions for the prevention and treatment of inflammatory disorders of the colon
WO2008074080A1 (en) Composition and method for treatment of ibs
US6248307B1 (en) Compositions and treatment for alleviation of symptoms associated with menopause
EP1274414B1 (en) Nasal administration of metoclopramide for the treatment of gastroparesis
US8748489B2 (en) Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent
US4476121A (en) Bowel evacuant and method of treating constipation
US7094762B2 (en) Use of ribose to treat fibromyalgia
WO2008141368A1 (en) Combination laxative compositions comprising a colonic stimulant and a bulking laxative
AU2017206073A1 (en) Food based delivery of therapeutic agent for treatment of hepatic encephalopathy
CN1895520B (en) Gastrin magnesium granules and preparation thereof
WO2008119127A1 (en) Herbal compositions and methods for treating menorrhagia
CN111184867A (en) Chemical medicine composition for treating helicobacter pylori infection
EP1095658A2 (en) Use of ribose to treat fibromyalgia
EP3737245A1 (en) Solid concentrated constipation treatment formulations
JPH11116495A (en) Vitamin combination drug improved in touch on taking
KR20050001548A (en) Pharmaceutical compositions for antidiarrhea
JP2021172612A (en) Pharmaceutical comprising combination of oxytocin and proton pump inhibitor
US20110245212A1 (en) Methods of alleviating the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
CN100473392C (en) Compound clore basil preparation
CA3000981A1 (en) Pharmaceutical compositions containing cannabis, uses thereof and methods for improving digestion and/or treating symptoms associated with gastrointestinal complications
KR20080068014A (en) Preparation for the treatment of diarrehoea
JP2007230990A (en) Therapeutic agent for meniere&#39;s disease
JP2019011279A (en) Diarrhea inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07845408

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 577102

Country of ref document: NZ

Ref document number: 2007335255

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007335255

Country of ref document: AU

Date of ref document: 20071219

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07845408

Country of ref document: EP

Kind code of ref document: A1